JP2004510750A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004510750A5 JP2004510750A5 JP2002532258A JP2002532258A JP2004510750A5 JP 2004510750 A5 JP2004510750 A5 JP 2004510750A5 JP 2002532258 A JP2002532258 A JP 2002532258A JP 2002532258 A JP2002532258 A JP 2002532258A JP 2004510750 A5 JP2004510750 A5 JP 2004510750A5
- Authority
- JP
- Japan
- Prior art keywords
- agonist
- ppardelta
- activator
- ppar delta
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010015181 PPAR delta Proteins 0.000 claims 7
- 239000012190 activator Substances 0.000 claims 5
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- YDBLKRPLXZNVNB-UHFFFAOYSA-N GW 501516 Chemical group CC=1N=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1CSC1=CC=C(OCC(O)=O)C(C)=C1 YDBLKRPLXZNVNB-UHFFFAOYSA-N 0.000 claims 1
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0024361.8A GB0024361D0 (en) | 2000-10-05 | 2000-10-05 | Medicaments |
| PCT/GB2001/004373 WO2002028434A2 (en) | 2000-10-05 | 2001-10-01 | Use of a ppar delta activator for treating inflammatory conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004510750A JP2004510750A (ja) | 2004-04-08 |
| JP2004510750A5 true JP2004510750A5 (https=) | 2005-12-22 |
| JP4106263B2 JP4106263B2 (ja) | 2008-06-25 |
Family
ID=9900709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002532258A Expired - Fee Related JP4106263B2 (ja) | 2000-10-05 | 2001-10-01 | 炎症性の状態の治療のためのｐｐａｒデルタ活性化因子の使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7084161B2 (https=) |
| EP (1) | EP1324774B1 (https=) |
| JP (1) | JP4106263B2 (https=) |
| AT (1) | ATE318615T1 (https=) |
| AU (1) | AU2001292046A1 (https=) |
| DE (1) | DE60117584T2 (https=) |
| ES (1) | ES2259675T3 (https=) |
| GB (1) | GB0024361D0 (https=) |
| WO (1) | WO2002028434A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002070011A2 (en) * | 2001-02-02 | 2002-09-12 | Smithkline Beecham Corporation | Treatment of ppar mediated diseases |
| WO2002100351A2 (en) * | 2001-06-11 | 2002-12-19 | Merck & Co., Inc. | A method for treating inflammatory diseases by administering a ppar-delta agonist |
| BR0212512A (pt) | 2001-09-14 | 2004-10-26 | Tularik Inc | Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta |
| FR2836829B1 (fr) * | 2002-03-11 | 2005-11-25 | Bio Merieux | Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro |
| JP2007530703A (ja) * | 2004-04-01 | 2007-11-01 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | Ｍｓおよびその他の脱髄疾患を治療するためのペルオキシソーム増殖因子活性化受容体デルタアゴニストの使用 |
| ES2352085T3 (es) | 2004-05-05 | 2011-02-15 | High Point Pharmaceuticals, Llc | Nuevos compuestos, su preparación y uso. |
| WO2005105736A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Novel compounds, their preparation and use |
| WO2006020830A2 (en) | 2004-08-12 | 2006-02-23 | Amgen Inc. | Bisaryl-sulfonamides |
| ATE529404T1 (de) | 2005-06-30 | 2011-11-15 | High Point Pharmaceuticals Llc | Phenoxyessigsäuren als ppar-delta-aktivatoren |
| BRPI0620468A2 (pt) | 2005-12-22 | 2011-11-08 | Transtech Pharma, Inc. | ácidos fenóxi acéticos como ativadores de ppar delta |
| WO2007101864A2 (en) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Compounds that modulate ppar activity, their preparation and use |
| US20080004281A1 (en) * | 2006-06-28 | 2008-01-03 | Kalypsys, Inc. | Methods for the modulation of crp by the selective modulation of ppar delta |
| CA2687957C (en) * | 2007-05-21 | 2014-11-25 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical containing ppar.delta. agonist |
| CN102724978A (zh) * | 2009-08-14 | 2012-10-10 | 塞伦尼斯治疗公司 | 用于治疗或预防炎症或能量代谢/产生相关疾病的PPARδ配体的用途 |
| KR102038866B1 (ko) * | 2012-12-24 | 2019-10-31 | 서울대학교산학협력단 | ＰＰＡＲδ 활성물질의 항생제, 화상 및 창상 치료제, 당뇨성 족부궤양 치료제로서의 용도 |
| WO2015035171A1 (en) | 2013-09-09 | 2015-03-12 | High Point Pharmaceuticals, Llc | Use of a ppar-delta agonist for treating muscle atrophy |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| KR102750722B1 (ko) * | 2022-03-16 | 2025-01-09 | 재단법인 대구경북첨단의료산업진흥재단 | 싸이아다이아졸 화합물 및 이를 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997028149A1 (en) * | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| CA2295930C (en) * | 1997-07-24 | 2010-12-14 | Yamanouchi Pharmaceutical Co., Ltd. | Pharmaceutical compositions having cholesterol-lowering effect |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
-
2000
- 2000-10-05 GB GBGB0024361.8A patent/GB0024361D0/en not_active Ceased
-
2001
- 2001-10-01 DE DE60117584T patent/DE60117584T2/de not_active Expired - Fee Related
- 2001-10-01 WO PCT/GB2001/004373 patent/WO2002028434A2/en not_active Ceased
- 2001-10-01 AU AU2001292046A patent/AU2001292046A1/en not_active Abandoned
- 2001-10-01 ES ES01972266T patent/ES2259675T3/es not_active Expired - Lifetime
- 2001-10-01 EP EP01972266A patent/EP1324774B1/en not_active Expired - Lifetime
- 2001-10-01 US US10/398,629 patent/US7084161B2/en not_active Expired - Fee Related
- 2001-10-01 AT AT01972266T patent/ATE318615T1/de not_active IP Right Cessation
- 2001-10-01 JP JP2002532258A patent/JP4106263B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004510750A5 (https=) | ||
| JP2006526590A5 (https=) | ||
| JP2002543065A5 (https=) | ||
| JP2008543854A5 (https=) | ||
| JP2004535466A5 (https=) | ||
| JP2002161074A5 (https=) | ||
| KR960041168A (ko) | 베타-아드레날린 효능성 작용물질 | |
| JP2006517939A5 (https=) | ||
| JP2004516314A5 (https=) | ||
| JP2005511547A5 (https=) | ||
| JP2006182786A5 (https=) | ||
| CN1633285A (zh) | 组合物 | |
| CA2436846A1 (en) | Thioether substituted imidazoquinolines | |
| JP2018135343A5 (https=) | ||
| JP2008524127A5 (https=) | ||
| CN1284877A (zh) | 胃保护性奥美拉唑微粒、其制备方法及药物制剂 | |
| CN1152025C (zh) | 取代的苄基噻唑烷-2,4-二酮衍生物 | |
| JP2005527576A5 (https=) | ||
| JP2015508068A5 (https=) | ||
| JP2004510749A5 (https=) | ||
| CN1210027C (zh) | 治疗溃疡的药物组合物及其应用 | |
| JP2005511516A5 (https=) | ||
| JP2005517677A5 (https=) | ||
| EP1612208A3 (en) | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | |
| JP2004532828A5 (https=) |